PPARD and metabolic syndrome: Thus, in contrast to the earlier notion of the therapeutic potential of PPARβ/δ agonists as “exercise mimetics” and potential treatments for metabolic syndrome [186,187,188], extreme caution should be applied when considering PPARβ/δ agonists for therapeutic purposes given their pro-tumorigenic properties.